言语治疗与rTMS在慢性与亚急性卒中后失语中的差异效应:NORTHSTAR-CA试验结果
结果显示所有组语言结局均改善,但仅在亚急性期rTMS对命名恢复有显著附加获益,慢性期无显著rTMS效应。
要点
- rTMS联合SLT仅在亚急性卒中后失语中显著改善命名恢复。
- 慢性期患者未观察到rTMS的显著附加效应。
- 不良事件罕见且轻微,组间无差异。
核心结论
- rTMS联合SLT仅在亚急性期对命名恢复产生显著附加获益,慢性期无显著rTMS效应。
- 所有组语言结局均显著改善,与治疗和恢复阶段无关。
主要发现
- 不良事件罕见、轻微,组间无差异。
- 治疗结束后30天随访时,刺激与恢复阶段对命名恢复存在显著交互作用(P<.001)。
- 亚急性期rTMS命名恢复(Mdn=1.91/IQR=.77)大于慢性期(Mdn=.15/IQR=1.68/P=.015)。
- 慢性失语组无显著rTMS效应。
关键数值与推荐
- 主要结局为命名、语义流畅性和理解测试的Z分数变化及不良事件频率。
- 意向性治疗分析检验治疗后第1天和第30天的组间效应。
临床怎么用
- 对亚急性卒中后失语患者,可考虑在SLT基础上联合对侧1-Hz rTMS以促进命名恢复。
- 慢性期患者不建议常规添加该rTMS方案,需个体化评估。
局限性
- 结果需在更大规模研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & OBJECTIVE: Contralesional 1-Hz repetitive transcranial magnetic stimulation (rTMS) over the right pars triangularis combined with speech-language therapy (SLT) has shown positive results on the recovery of naming in subacute (5-45 days) post-stroke aphasia. NORTHSTAR-CA is an extension of the previously reported NORTHSTAR trial to chronic aphasia (>6 months post-stroke) designed to compare the effectiveness of the same rTMS protocol in both phases. METHODS: Sixty-seven patients with left middle cerebral artery infarcts (28 chronic, 39 subacute) were recruited (01-2014 to 07-2019) and randomized to receive rTMS (N = 34) or sham stimulation (N = 33) with SLT for 10 days. Primary outcome variables were Z-score changes in naming, semantic fluency and comprehension tests and adverse event frequency. Intention-to-treat analyses tested between-group effects at days 1 and 30 post-treatment. Chronic and subacute results were compared. RESULTS: Adverse events were rare, mild, and did not differ between groups. Language outcomes improved significantly in all groups irrespective of treatment and recovery phase. At 30-day follow-up, there was a significant interaction of stimulation and recovery phase on naming recovery (P <.001). Naming recovery with rTMS was larger in subacute (Mdn = 1.91/IQR = .77) than chronic patients (Mdn = .15/IQR = 1.68/P = .015). There was no significant rTMS effect in the chronic aphasia group. CONCLUSIONS: The addition of rTMS to SLT led to significant supplemental gains in naming recovery in the subacute phase only. While this needs confirmation in larger studies, our results clarify neuromodulatory vs training-induced effects and indicate a possible window of opportunity for contralesional inhibitory stimulation interventions in post-stroke aphasia. NORTHSTAR TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT02020421.
引用
- Zumbansen A, Kneifel H, Lazzouni L, et al. Differential Effects of Speech and Language Therapy and rTMS in Chronic Versus Subacute Post-stroke Aphasia: Results of the NORTHSTAR-CA Trial. Neurorehabil Neural Repair. 2022. PMID: 35337223. doi:10.1177/15459683211065448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。